BIRS (Biomarkers in Rett Syndrome): a Long-term Observational Multicenter Study of the Natural History of Rett Syndrome to Define New Clinical and Instrumental Biomarkers

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

Rett syndrome (RTT) is an X-linked genetic disorder that causes severe neurological development disorder. In its classic form, it seems to affect almost exclusively females with an incidence of up to one in 10,000 females. Patients affected by Rett Syndrome can present a wide range of symptoms, in different combinations and of varying intensity, such as slowed growth of head circumference, abnormalities in walking and balance, loss of functional use of the hands often replaced by repetitive and stereotyped hand movements like hand washing, loss of communicative-relational skills including expressive language, epilepsy, breathing abnormalities, and osteo-muscular alterations. In light of the growing potential of clinical therapies, identification and early diagnosis are considered essential. Many disease modification strategies have been achieved through translational research studies and clinical trials that have allowed the recognition of the most effective therapeutic and clinical interventions to date. This study arises from the need to advance in the understanding of the pathogenesis of RTT through a multicentric collaboration in order to (a) identify early biomarkers of RTT (b) delve into the alterations of interconnectivity, crucial for understanding the loss of motor functions and language through systematic collection of anamnestic, genetic, and clinical-instrumental data. The aim is to provide a valuable contribution to the study of the clinical phenotype of Rett and the identification of early interventions.

Eligibility
Participation Requirements
Sex: Female
Maximum Age: 18
Healthy Volunteers: t
View:

• All subjects aged between 0 and 18 years with Rett Syndrome, classic (mutation of the MECP2 gene) and Rett variants (CDKL5, FOXG1 mutations, and other MECP2 mutations), genetically confirmed:

‣ newly diagnosed

⁃ previously diagnosed if possessing data recorded and stored in the enrollment centers' records;

⁃ upon written informed consent from the parents.

• Siblings of the probands of any age who will undergo EEG registration will also be enrolled.

Locations
Other Locations
Ireland
Trinity College Institute of Neuroscience, Lloyd Building, D2
RECRUITING
Dublin
Italy
IRCCS Fondazione Stella Maris
RECRUITING
Calambrone
AOU Meyer
RECRUITING
Florence
Ospedale Versilia Centro di Riferimento
RECRUITING
Lido Di Camaiore
Contact Information
Primary
Roberta Battini
rbattini@fsm.unipi.it
050886282
Time Frame
Start Date: 2020-08-03
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 100
Related Therapeutic Areas
Sponsors
Collaborators: University of Dublin, Trinity College, Azienda USL Toscana Nord Ovest, Meyer Children's Hospital IRCCS
Leads: IRCCS Fondazione Stella Maris

This content was sourced from clinicaltrials.gov